Study to Evaluate the Relative Bioavailability of Fixed-dose Combination Tablet Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) as a Whole Tablet, as a Split Tablet, and as Crushed Tablet in Healthy Adult Participants

NCT02984852 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Darunavir (DRV)
DRUG: Cobicistat (COBI)
DRUG: Emtricitabine (FTC)
DRUG: Tenofovir Alafenamide (TAF)

Sponsor

Janssen Scientific Affairs, LLC